MedTrace Logo

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

NCT00285376 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2008-02-21

No results posted yet for this study

Summary

This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

vilazodone

titration to 40mg tablets qd for 8 weeks

Sponsors & Collaborators

  • Genaissance Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Carol Reed, M.D. · Genaissance Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285376 on ClinicalTrials.gov